The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on injection long-acting PrEP.
Men reported little to no stigma or anxiety concerns about using pre-exposure prophylaxis (PrEP) to prevent HIV when using Apretude (cabotegravir), according to a poster at ID Week 2024, which is being held this week in Los Angeles.
Developed by ViiV Healthcare, Apretude is a long-acting medication used to reduce the risk of getting HIV-1 in adults and adolescents. It is given by injection by a healthcare professional every two months, after two initial injections in the first month.
As part of the phase 4 PILLAR study, 201 men who have sex with men and transgender men from 17 clinics were surveyed between May 2022 and August 2023 about the stigma of taking PrEP, as well as about pain after injection. Researchers also interviewed 52 of these participants.
Stigma and anxiety were both assessed through questions that explored perceptions around concerns and experience with both oral medication and long-acting injections. Stigma was also assessed using the validated HIV PrEP Stigma Scale.
Researchers, led by Hadrian Holder, M.D., with Southwest Community Health Center in Bridgeport, Conn., found that at baseline, 15% and 29% of participants reported experiencing stigma and anxiety with oral PrEP vs. 0% and 2% with Apretude at month 6 of the study. Additionally, at baseline, 53% to 54% of participants reported concerns around forgetting to take and running out of oral PrEP medication.
Most interviewed participants (78%) discussed the benefit or value of more frequent clinic visits to receive the injections for the long-acting medication. They specifically mentioned having more interaction with healthcare providers, which facilitated discussion of other health issues, more frequent sexually transmitted infection testing, which provided reassurance, and the building of rapport and a relationship with staff at the clinic.
In the surveys, participants reported that the level of pain for the first injection was generally higher than that reported for their most recent injection. During the interviews, 39% mentioned injection site soreness. But most participants reported returning to their usual daily activities immediately following the injections.
A previous review of PILLAR found that most of the participants (71%) had taken oral PrEP in the last six months. Most (63%) had heard of a long-acting cabotegravir before the study from providers (48%), friends (12%) and commercials (13%). Interviewed participants discussed providers as the key influencer in deciding to use a long-acting cabotegravir (85%), followed by themselves (31%), partners (29%) and commercials (25%).
The PILLAR study was sponsored by ViiV Healthcare.
Shifting Funding Priorities Could Mean More HIV Infections and Deaths | ID Week 2024
October 16th 2024The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.
Read More
With Its Future in Doubt, One of the Architects Makes a Case for PEPFAR | IDWeek 2023
October 15th 2023Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.
Read More
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.
Read More
Cytomegalovirus Update: Why Isn’t There a Vaccine? | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.
Read More